elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q37554103-89D401BF-91DE-43CE-BA8C-C7F32314D9E5
Q37554103-89D401BF-91DE-43CE-BA8C-C7F32314D9E5
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37554103-89D401BF-91DE-43CE-BA8C-C7F32314D9E5
One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
P2860
Q37554103-89D401BF-91DE-43CE-BA8C-C7F32314D9E5
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37554103-89D401BF-91DE-43CE-BA8C-C7F32314D9E5
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
ba708e254438b3e2a9735f489bfab5425247b66d
P2860
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.